nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CHRM3—ureter—urinary bladder cancer	0.0827	0.235	CbGeAlD
Tolterodine—CHRM3—muscle of abdomen—urinary bladder cancer	0.0595	0.169	CbGeAlD
Tolterodine—CYP3A4—Thiotepa—urinary bladder cancer	0.0281	0.36	CbGbCtD
Tolterodine—CYP2C19—urine—urinary bladder cancer	0.025	0.071	CbGeAlD
Tolterodine—CYP2C9—urine—urinary bladder cancer	0.0194	0.055	CbGeAlD
Tolterodine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0157	0.201	CbGbCtD
Tolterodine—CYP3A4—urine—urinary bladder cancer	0.0148	0.042	CbGeAlD
Tolterodine—CYP2D6—urine—urinary bladder cancer	0.0145	0.0413	CbGeAlD
Tolterodine—CYP2C9—Cisplatin—urinary bladder cancer	0.0133	0.171	CbGbCtD
Tolterodine—CHRM5—epithelium—urinary bladder cancer	0.0127	0.036	CbGeAlD
Tolterodine—Urinary retention—Valrubicin—urinary bladder cancer	0.0125	0.0274	CcSEcCtD
Tolterodine—CHRM2—prostate gland—urinary bladder cancer	0.0118	0.0337	CbGeAlD
Tolterodine—CHRM1—prostate gland—urinary bladder cancer	0.0108	0.0306	CbGeAlD
Tolterodine—Dysuria—Valrubicin—urinary bladder cancer	0.0106	0.0233	CcSEcCtD
Tolterodine—Urinary tract infection—Valrubicin—urinary bladder cancer	0.00982	0.0216	CcSEcCtD
Tolterodine—CHRM3—prostate gland—urinary bladder cancer	0.00965	0.0274	CbGeAlD
Tolterodine—Oedema peripheral—Valrubicin—urinary bladder cancer	0.00893	0.0196	CcSEcCtD
Tolterodine—KCNH2—prostate gland—urinary bladder cancer	0.00855	0.0243	CbGeAlD
Tolterodine—CYP2D6—Doxorubicin—urinary bladder cancer	0.00816	0.105	CbGbCtD
Tolterodine—Memory impairment—Thiotepa—urinary bladder cancer	0.00797	0.0175	CcSEcCtD
Tolterodine—Flatulence—Valrubicin—urinary bladder cancer	0.00778	0.0171	CcSEcCtD
Tolterodine—CYP3A4—Etoposide—urinary bladder cancer	0.00761	0.0975	CbGbCtD
Tolterodine—Influenza-like symptoms—Gemcitabine—urinary bladder cancer	0.00737	0.0162	CcSEcCtD
Tolterodine—KCNH2—seminal vesicle—urinary bladder cancer	0.00723	0.0206	CbGeAlD
Tolterodine—CHRM3—smooth muscle tissue—urinary bladder cancer	0.00683	0.0194	CbGeAlD
Tolterodine—Chest pain—Valrubicin—urinary bladder cancer	0.00672	0.0148	CcSEcCtD
Tolterodine—CHRM3—renal system—urinary bladder cancer	0.00658	0.0187	CbGeAlD
Tolterodine—Dementia—Methotrexate—urinary bladder cancer	0.00656	0.0144	CcSEcCtD
Tolterodine—CHRM3—urethra—urinary bladder cancer	0.00646	0.0184	CbGeAlD
Tolterodine—Infection—Carboplatin—urinary bladder cancer	0.00593	0.013	CcSEcCtD
Tolterodine—CHRM1—female reproductive system—urinary bladder cancer	0.00588	0.0167	CbGeAlD
Tolterodine—Musculoskeletal discomfort—Valrubicin—urinary bladder cancer	0.00587	0.0129	CcSEcCtD
Tolterodine—KCNH2—renal system—urinary bladder cancer	0.00583	0.0166	CbGeAlD
Tolterodine—KCNH2—urethra—urinary bladder cancer	0.00573	0.0163	CbGeAlD
Tolterodine—Feeling abnormal—Valrubicin—urinary bladder cancer	0.00531	0.0117	CcSEcCtD
Tolterodine—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.00527	0.0116	CcSEcCtD
Tolterodine—CHRM3—female reproductive system—urinary bladder cancer	0.00527	0.015	CbGeAlD
Tolterodine—CYP3A4—Doxorubicin—urinary bladder cancer	0.00519	0.0665	CbGbCtD
Tolterodine—Influenza like illness—Gemcitabine—urinary bladder cancer	0.00511	0.0112	CcSEcCtD
Tolterodine—Pain—Carboplatin—urinary bladder cancer	0.0051	0.0112	CcSEcCtD
Tolterodine—Abdominal pain—Valrubicin—urinary bladder cancer	0.00509	0.0112	CcSEcCtD
Tolterodine—KCNH2—female reproductive system—urinary bladder cancer	0.00467	0.0133	CbGeAlD
Tolterodine—Asthenia—Valrubicin—urinary bladder cancer	0.00462	0.0102	CcSEcCtD
Tolterodine—Confusional state—Mitomycin—urinary bladder cancer	0.00448	0.00984	CcSEcCtD
Tolterodine—Oedema—Mitomycin—urinary bladder cancer	0.00444	0.00976	CcSEcCtD
Tolterodine—CYP2C19—vagina—urinary bladder cancer	0.00443	0.0126	CbGeAlD
Tolterodine—Diarrhoea—Valrubicin—urinary bladder cancer	0.00441	0.00969	CcSEcCtD
Tolterodine—Urinary retention—Thiotepa—urinary bladder cancer	0.00432	0.0095	CcSEcCtD
Tolterodine—Dizziness—Valrubicin—urinary bladder cancer	0.00426	0.00937	CcSEcCtD
Tolterodine—KCNH2—vagina—urinary bladder cancer	0.00422	0.012	CbGeAlD
Tolterodine—Disorientation—Fluorouracil—urinary bladder cancer	0.0042	0.00923	CcSEcCtD
Tolterodine—Headache—Valrubicin—urinary bladder cancer	0.00404	0.00887	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Gemcitabine—urinary bladder cancer	0.00395	0.00868	CcSEcCtD
Tolterodine—Somnolence—Mitomycin—urinary bladder cancer	0.00395	0.00868	CcSEcCtD
Tolterodine—Fatigue—Mitomycin—urinary bladder cancer	0.00383	0.00841	CcSEcCtD
Tolterodine—Pain—Mitomycin—urinary bladder cancer	0.0038	0.00835	CcSEcCtD
Tolterodine—CYP2C9—female reproductive system—urinary bladder cancer	0.00379	0.0108	CbGeAlD
Tolterodine—Anaphylactoid reaction—Cisplatin—urinary bladder cancer	0.00368	0.00809	CcSEcCtD
Tolterodine—Dysuria—Thiotepa—urinary bladder cancer	0.00367	0.00807	CcSEcCtD
Tolterodine—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00366	0.00804	CcSEcCtD
Tolterodine—CYP3A4—renal system—urinary bladder cancer	0.00361	0.0103	CbGeAlD
Tolterodine—Weight increased—Thiotepa—urinary bladder cancer	0.00357	0.00785	CcSEcCtD
Tolterodine—CYP2D6—renal system—urinary bladder cancer	0.00356	0.0101	CbGeAlD
Tolterodine—Dry skin—Fluorouracil—urinary bladder cancer	0.00344	0.00757	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Etoposide—urinary bladder cancer	0.00337	0.00741	CcSEcCtD
Tolterodine—Asthenia—Mitomycin—urinary bladder cancer	0.00318	0.007	CcSEcCtD
Tolterodine—Hallucination—Thiotepa—urinary bladder cancer	0.00313	0.00687	CcSEcCtD
Tolterodine—Diarrhoea—Mitomycin—urinary bladder cancer	0.00304	0.00668	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.00302	0.00663	CcSEcCtD
Tolterodine—Dizziness—Mitomycin—urinary bladder cancer	0.00294	0.00645	CcSEcCtD
Tolterodine—CYP3A4—female reproductive system—urinary bladder cancer	0.00289	0.00822	CbGeAlD
Tolterodine—CYP2D6—female reproductive system—urinary bladder cancer	0.00285	0.00809	CbGeAlD
Tolterodine—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.00281	0.00619	CcSEcCtD
Tolterodine—Headache—Mitomycin—urinary bladder cancer	0.00278	0.00611	CcSEcCtD
Tolterodine—KCNH2—lymph node—urinary bladder cancer	0.00273	0.00776	CbGeAlD
Tolterodine—Sinusitis—Fluorouracil—urinary bladder cancer	0.00272	0.00597	CcSEcCtD
Tolterodine—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.0026	0.00572	CcSEcCtD
Tolterodine—Influenza like illness—Epirubicin—urinary bladder cancer	0.00245	0.00538	CcSEcCtD
Tolterodine—Visual impairment—Cisplatin—urinary bladder cancer	0.00237	0.00522	CcSEcCtD
Tolterodine—Arthralgia—Thiotepa—urinary bladder cancer	0.00233	0.00512	CcSEcCtD
Tolterodine—Dry eye—Epirubicin—urinary bladder cancer	0.00233	0.00512	CcSEcCtD
Tolterodine—Anxiety—Thiotepa—urinary bladder cancer	0.00232	0.0051	CcSEcCtD
Tolterodine—Flushing—Cisplatin—urinary bladder cancer	0.00229	0.00503	CcSEcCtD
Tolterodine—Influenza like illness—Doxorubicin—urinary bladder cancer	0.00226	0.00498	CcSEcCtD
Tolterodine—Confusional state—Thiotepa—urinary bladder cancer	0.00225	0.00495	CcSEcCtD
Tolterodine—Infection—Thiotepa—urinary bladder cancer	0.00222	0.00488	CcSEcCtD
Tolterodine—Abnormal vision—Epirubicin—urinary bladder cancer	0.0022	0.00483	CcSEcCtD
Tolterodine—Tachycardia—Thiotepa—urinary bladder cancer	0.00218	0.00479	CcSEcCtD
Tolterodine—Dry eye—Doxorubicin—urinary bladder cancer	0.00215	0.00473	CcSEcCtD
Tolterodine—Flatulence—Cisplatin—urinary bladder cancer	0.00211	0.00465	CcSEcCtD
Tolterodine—Flushing—Etoposide—urinary bladder cancer	0.00209	0.00461	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00203	0.00447	CcSEcCtD
Tolterodine—Abnormal vision—Doxorubicin—urinary bladder cancer	0.00203	0.00447	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.00202	0.00444	CcSEcCtD
Tolterodine—Somnolence—Thiotepa—urinary bladder cancer	0.00198	0.00436	CcSEcCtD
Tolterodine—Dyspepsia—Thiotepa—urinary bladder cancer	0.00196	0.00432	CcSEcCtD
Tolterodine—Arthralgia—Gemcitabine—urinary bladder cancer	0.00196	0.00431	CcSEcCtD
Tolterodine—Chest pain—Gemcitabine—urinary bladder cancer	0.00196	0.00431	CcSEcCtD
Tolterodine—Chest pain—Fluorouracil—urinary bladder cancer	0.00193	0.00423	CcSEcCtD
Tolterodine—Fatigue—Thiotepa—urinary bladder cancer	0.00192	0.00423	CcSEcCtD
Tolterodine—Pain—Thiotepa—urinary bladder cancer	0.00191	0.0042	CcSEcCtD
Tolterodine—Constipation—Thiotepa—urinary bladder cancer	0.00191	0.0042	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.00189	0.00415	CcSEcCtD
Tolterodine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00188	0.00413	CcSEcCtD
Tolterodine—Oedema—Gemcitabine—urinary bladder cancer	0.00188	0.00413	CcSEcCtD
Tolterodine—Infection—Gemcitabine—urinary bladder cancer	0.00187	0.0041	CcSEcCtD
Tolterodine—Confusional state—Fluorouracil—urinary bladder cancer	0.00186	0.00409	CcSEcCtD
Tolterodine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00185	0.00406	CcSEcCtD
Tolterodine—Oedema—Fluorouracil—urinary bladder cancer	0.00185	0.00406	CcSEcCtD
Tolterodine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00184	0.00404	CcSEcCtD
Tolterodine—Infection—Fluorouracil—urinary bladder cancer	0.00183	0.00403	CcSEcCtD
Tolterodine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00183	0.00401	CcSEcCtD
Tolterodine—Anxiety—Cisplatin—urinary bladder cancer	0.00182	0.004	CcSEcCtD
Tolterodine—Tachycardia—Fluorouracil—urinary bladder cancer	0.0018	0.00396	CcSEcCtD
Tolterodine—Vertigo—Etoposide—urinary bladder cancer	0.00177	0.00388	CcSEcCtD
Tolterodine—Abdominal pain—Thiotepa—urinary bladder cancer	0.00176	0.00388	CcSEcCtD
Tolterodine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00175	0.00385	CcSEcCtD
Tolterodine—Oedema—Cisplatin—urinary bladder cancer	0.00175	0.00385	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.00175	0.00384	CcSEcCtD
Tolterodine—Infection—Cisplatin—urinary bladder cancer	0.00174	0.00382	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00171	0.00376	CcSEcCtD
Tolterodine—Tachycardia—Cisplatin—urinary bladder cancer	0.00171	0.00376	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00168	0.0037	CcSEcCtD
Tolterodine—Dry skin—Epirubicin—urinary bladder cancer	0.00168	0.00369	CcSEcCtD
Tolterodine—Chest pain—Etoposide—urinary bladder cancer	0.00167	0.00368	CcSEcCtD
Tolterodine—Somnolence—Gemcitabine—urinary bladder cancer	0.00167	0.00367	CcSEcCtD
Tolterodine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00164	0.00362	CcSEcCtD
Tolterodine—Somnolence—Fluorouracil—urinary bladder cancer	0.00164	0.00361	CcSEcCtD
Tolterodine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00163	0.00357	CcSEcCtD
Tolterodine—Fatigue—Gemcitabine—urinary bladder cancer	0.00162	0.00356	CcSEcCtD
Tolterodine—Confusional state—Etoposide—urinary bladder cancer	0.00162	0.00355	CcSEcCtD
Tolterodine—Pain—Gemcitabine—urinary bladder cancer	0.00161	0.00353	CcSEcCtD
Tolterodine—Constipation—Gemcitabine—urinary bladder cancer	0.00161	0.00353	CcSEcCtD
Tolterodine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.0016	0.00353	CcSEcCtD
Tolterodine—Asthenia—Thiotepa—urinary bladder cancer	0.0016	0.00352	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00159	0.00351	CcSEcCtD
Tolterodine—Infection—Etoposide—urinary bladder cancer	0.00159	0.0035	CcSEcCtD
Tolterodine—Dysuria—Methotrexate—urinary bladder cancer	0.00158	0.00347	CcSEcCtD
Tolterodine—Pain—Fluorouracil—urinary bladder cancer	0.00158	0.00347	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.00157	0.00345	CcSEcCtD
Tolterodine—Tachycardia—Etoposide—urinary bladder cancer	0.00156	0.00344	CcSEcCtD
Tolterodine—Dry skin—Doxorubicin—urinary bladder cancer	0.00155	0.00341	CcSEcCtD
Tolterodine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00155	0.0034	CcSEcCtD
Tolterodine—Diarrhoea—Thiotepa—urinary bladder cancer	0.00153	0.00336	CcSEcCtD
Tolterodine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00152	0.00335	CcSEcCtD
Tolterodine—Bronchitis—Epirubicin—urinary bladder cancer	0.00152	0.00334	CcSEcCtD
Tolterodine—Pain—Cisplatin—urinary bladder cancer	0.0015	0.00329	CcSEcCtD
Tolterodine—Dysuria—Epirubicin—urinary bladder cancer	0.00148	0.00325	CcSEcCtD
Tolterodine—Dizziness—Thiotepa—urinary bladder cancer	0.00148	0.00325	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.00147	0.00323	CcSEcCtD
Tolterodine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00144	0.00317	CcSEcCtD
Tolterodine—Weight increased—Epirubicin—urinary bladder cancer	0.00144	0.00316	CcSEcCtD
Tolterodine—Somnolence—Etoposide—urinary bladder cancer	0.00143	0.00313	CcSEcCtD
Tolterodine—Bronchitis—Doxorubicin—urinary bladder cancer	0.00141	0.00309	CcSEcCtD
Tolterodine—Headache—Thiotepa—urinary bladder cancer	0.0014	0.00307	CcSEcCtD
Tolterodine—Fatigue—Etoposide—urinary bladder cancer	0.00138	0.00304	CcSEcCtD
Tolterodine—Constipation—Etoposide—urinary bladder cancer	0.00137	0.00301	CcSEcCtD
Tolterodine—Pain—Etoposide—urinary bladder cancer	0.00137	0.00301	CcSEcCtD
Tolterodine—Urinary tract infection—Epirubicin—urinary bladder cancer	0.00137	0.00301	CcSEcCtD
Tolterodine—Dysuria—Doxorubicin—urinary bladder cancer	0.00137	0.00301	CcSEcCtD
Tolterodine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00136	0.00299	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.00136	0.00299	CcSEcCtD
Tolterodine—Asthenia—Gemcitabine—urinary bladder cancer	0.00135	0.00296	CcSEcCtD
Tolterodine—Weight increased—Doxorubicin—urinary bladder cancer	0.00133	0.00293	CcSEcCtD
Tolterodine—Sinusitis—Epirubicin—urinary bladder cancer	0.00132	0.00291	CcSEcCtD
Tolterodine—Feeling abnormal—Etoposide—urinary bladder cancer	0.00132	0.00291	CcSEcCtD
Tolterodine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00131	0.00288	CcSEcCtD
Tolterodine—Visual impairment—Methotrexate—urinary bladder cancer	0.0013	0.00286	CcSEcCtD
Tolterodine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00129	0.00284	CcSEcCtD
Tolterodine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00128	0.00282	CcSEcCtD
Tolterodine—Abdominal pain—Etoposide—urinary bladder cancer	0.00127	0.00279	CcSEcCtD
Tolterodine—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00127	0.00279	CcSEcCtD
Tolterodine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00126	0.00278	CcSEcCtD
Tolterodine—Asthenia—Cisplatin—urinary bladder cancer	0.00126	0.00276	CcSEcCtD
Tolterodine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00125	0.00274	CcSEcCtD
Tolterodine—Sinusitis—Doxorubicin—urinary bladder cancer	0.00122	0.00269	CcSEcCtD
Tolterodine—Dizziness—Fluorouracil—urinary bladder cancer	0.00122	0.00268	CcSEcCtD
Tolterodine—Visual impairment—Epirubicin—urinary bladder cancer	0.00122	0.00268	CcSEcCtD
Tolterodine—Diarrhoea—Cisplatin—urinary bladder cancer	0.0012	0.00263	CcSEcCtD
Tolterodine—Hypersensitivity—Etoposide—urinary bladder cancer	0.00118	0.0026	CcSEcCtD
Tolterodine—Headache—Gemcitabine—urinary bladder cancer	0.00118	0.00259	CcSEcCtD
Tolterodine—Flushing—Epirubicin—urinary bladder cancer	0.00117	0.00258	CcSEcCtD
Tolterodine—Headache—Fluorouracil—urinary bladder cancer	0.00116	0.00254	CcSEcCtD
Tolterodine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00115	0.00254	CcSEcCtD
Tolterodine—Asthenia—Etoposide—urinary bladder cancer	0.00115	0.00253	CcSEcCtD
Tolterodine—Visual impairment—Doxorubicin—urinary bladder cancer	0.00113	0.00248	CcSEcCtD
Tolterodine—Diarrhoea—Etoposide—urinary bladder cancer	0.0011	0.00241	CcSEcCtD
Tolterodine—Flushing—Doxorubicin—urinary bladder cancer	0.00109	0.00239	CcSEcCtD
Tolterodine—Flatulence—Epirubicin—urinary bladder cancer	0.00109	0.00239	CcSEcCtD
Tolterodine—Dizziness—Etoposide—urinary bladder cancer	0.00106	0.00233	CcSEcCtD
Tolterodine—Vertigo—Methotrexate—urinary bladder cancer	0.00106	0.00232	CcSEcCtD
Tolterodine—Headache—Etoposide—urinary bladder cancer	0.001	0.00221	CcSEcCtD
Tolterodine—Flatulence—Doxorubicin—urinary bladder cancer	0.001	0.00221	CcSEcCtD
Tolterodine—Arthralgia—Methotrexate—urinary bladder cancer	0.001	0.0022	CcSEcCtD
Tolterodine—Chest pain—Methotrexate—urinary bladder cancer	0.001	0.0022	CcSEcCtD
Tolterodine—Vertigo—Epirubicin—urinary bladder cancer	0.000989	0.00218	CcSEcCtD
Tolterodine—Palpitations—Epirubicin—urinary bladder cancer	0.000973	0.00214	CcSEcCtD
Tolterodine—Confusional state—Methotrexate—urinary bladder cancer	0.000968	0.00213	CcSEcCtD
Tolterodine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00096	0.00211	CcSEcCtD
Tolterodine—Infection—Methotrexate—urinary bladder cancer	0.000954	0.0021	CcSEcCtD
Tolterodine—Arthralgia—Epirubicin—urinary bladder cancer	0.000938	0.00206	CcSEcCtD
Tolterodine—Chest pain—Epirubicin—urinary bladder cancer	0.000938	0.00206	CcSEcCtD
Tolterodine—Anxiety—Epirubicin—urinary bladder cancer	0.000934	0.00205	CcSEcCtD
Tolterodine—Dry mouth—Epirubicin—urinary bladder cancer	0.000917	0.00202	CcSEcCtD
Tolterodine—Vertigo—Doxorubicin—urinary bladder cancer	0.000915	0.00201	CcSEcCtD
Tolterodine—Confusional state—Epirubicin—urinary bladder cancer	0.000906	0.00199	CcSEcCtD
Tolterodine—Palpitations—Doxorubicin—urinary bladder cancer	0.0009	0.00198	CcSEcCtD
Tolterodine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000899	0.00198	CcSEcCtD
Tolterodine—Oedema—Epirubicin—urinary bladder cancer	0.000899	0.00198	CcSEcCtD
Tolterodine—Infection—Epirubicin—urinary bladder cancer	0.000893	0.00196	CcSEcCtD
Tolterodine—Tachycardia—Epirubicin—urinary bladder cancer	0.000877	0.00193	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000875	0.00192	CcSEcCtD
Tolterodine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000867	0.00191	CcSEcCtD
Tolterodine—Chest pain—Doxorubicin—urinary bladder cancer	0.000867	0.00191	CcSEcCtD
Tolterodine—Anxiety—Doxorubicin—urinary bladder cancer	0.000864	0.0019	CcSEcCtD
Tolterodine—Somnolence—Methotrexate—urinary bladder cancer	0.000854	0.00188	CcSEcCtD
Tolterodine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000848	0.00187	CcSEcCtD
Tolterodine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000845	0.00186	CcSEcCtD
Tolterodine—Confusional state—Doxorubicin—urinary bladder cancer	0.000839	0.00184	CcSEcCtD
Tolterodine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000832	0.00183	CcSEcCtD
Tolterodine—Oedema—Doxorubicin—urinary bladder cancer	0.000832	0.00183	CcSEcCtD
Tolterodine—Fatigue—Methotrexate—urinary bladder cancer	0.000828	0.00182	CcSEcCtD
Tolterodine—Infection—Doxorubicin—urinary bladder cancer	0.000826	0.00182	CcSEcCtD
Tolterodine—Pain—Methotrexate—urinary bladder cancer	0.000821	0.00181	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000819	0.0018	CcSEcCtD
Tolterodine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000812	0.00178	CcSEcCtD
Tolterodine—Somnolence—Epirubicin—urinary bladder cancer	0.000799	0.00176	CcSEcCtD
Tolterodine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000791	0.00174	CcSEcCtD
Tolterodine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000791	0.00174	CcSEcCtD
Tolterodine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000785	0.00173	CcSEcCtD
Tolterodine—Fatigue—Epirubicin—urinary bladder cancer	0.000775	0.0017	CcSEcCtD
Tolterodine—Pain—Epirubicin—urinary bladder cancer	0.000769	0.00169	CcSEcCtD
Tolterodine—Constipation—Epirubicin—urinary bladder cancer	0.000769	0.00169	CcSEcCtD
Tolterodine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000759	0.00167	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000758	0.00167	CcSEcCtD
Tolterodine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000741	0.00163	CcSEcCtD
Tolterodine—Somnolence—Doxorubicin—urinary bladder cancer	0.000739	0.00163	CcSEcCtD
Tolterodine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000735	0.00162	CcSEcCtD
Tolterodine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000732	0.00161	CcSEcCtD
Tolterodine—Fatigue—Doxorubicin—urinary bladder cancer	0.000717	0.00158	CcSEcCtD
Tolterodine—Constipation—Doxorubicin—urinary bladder cancer	0.000711	0.00156	CcSEcCtD
Tolterodine—Pain—Doxorubicin—urinary bladder cancer	0.000711	0.00156	CcSEcCtD
Tolterodine—Abdominal pain—Epirubicin—urinary bladder cancer	0.00071	0.00156	CcSEcCtD
Tolterodine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000708	0.00156	CcSEcCtD
Tolterodine—Asthenia—Methotrexate—urinary bladder cancer	0.000689	0.00152	CcSEcCtD
Tolterodine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000685	0.00151	CcSEcCtD
Tolterodine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00068	0.0015	CcSEcCtD
Tolterodine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000662	0.00146	CcSEcCtD
Tolterodine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000657	0.00145	CcSEcCtD
Tolterodine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000657	0.00144	CcSEcCtD
Tolterodine—Asthenia—Epirubicin—urinary bladder cancer	0.000645	0.00142	CcSEcCtD
Tolterodine—Dizziness—Methotrexate—urinary bladder cancer	0.000635	0.0014	CcSEcCtD
Tolterodine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000615	0.00135	CcSEcCtD
Tolterodine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000613	0.00135	CcSEcCtD
Tolterodine—Headache—Methotrexate—urinary bladder cancer	0.000602	0.00132	CcSEcCtD
Tolterodine—Asthenia—Doxorubicin—urinary bladder cancer	0.000597	0.00131	CcSEcCtD
Tolterodine—Dizziness—Epirubicin—urinary bladder cancer	0.000594	0.00131	CcSEcCtD
Tolterodine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000569	0.00125	CcSEcCtD
Tolterodine—Headache—Epirubicin—urinary bladder cancer	0.000563	0.00124	CcSEcCtD
Tolterodine—Dizziness—Doxorubicin—urinary bladder cancer	0.00055	0.00121	CcSEcCtD
Tolterodine—Headache—Doxorubicin—urinary bladder cancer	0.000521	0.00115	CcSEcCtD
Tolterodine—CHRM5—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.2e-05	0.000451	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—IL2—urinary bladder cancer	5.19e-05	0.00045	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	5.18e-05	0.000449	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TSC1—urinary bladder cancer	5.18e-05	0.000449	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TSC1—urinary bladder cancer	5.16e-05	0.000448	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	5.14e-05	0.000446	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TSC1—urinary bladder cancer	5.11e-05	0.000444	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—NCOR1—urinary bladder cancer	5.1e-05	0.000442	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	5.09e-05	0.000442	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—IL2—urinary bladder cancer	4.97e-05	0.000431	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—JAG1—urinary bladder cancer	4.93e-05	0.000428	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CXCL8—urinary bladder cancer	4.93e-05	0.000427	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—JAG1—urinary bladder cancer	4.92e-05	0.000426	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—JAG1—urinary bladder cancer	4.87e-05	0.000422	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—RRM2—urinary bladder cancer	4.86e-05	0.000422	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	4.81e-05	0.000417	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CXCL8—urinary bladder cancer	4.72e-05	0.000409	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—IL2—urinary bladder cancer	4.71e-05	0.000409	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TERT—urinary bladder cancer	4.69e-05	0.000407	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	4.69e-05	0.000406	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—GSTP1—urinary bladder cancer	4.66e-05	0.000404	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—IL2—urinary bladder cancer	4.51e-05	0.000391	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	4.5e-05	0.000391	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ENO2—urinary bladder cancer	4.5e-05	0.000391	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TERT—urinary bladder cancer	4.49e-05	0.00039	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.48e-05	0.000388	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	4.47e-05	0.000388	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	4.43e-05	0.000385	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	4.37e-05	0.000379	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—TYMS—urinary bladder cancer	4.33e-05	0.000376	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—FGFR3—urinary bladder cancer	4.31e-05	0.000374	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.3e-05	0.000373	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—NCOR1—urinary bladder cancer	4.28e-05	0.000371	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—GSTM1—urinary bladder cancer	4.28e-05	0.000371	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—ESR1—urinary bladder cancer	4.18e-05	0.000363	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—RHOA—urinary bladder cancer	4.17e-05	0.000362	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—RHOA—urinary bladder cancer	4.16e-05	0.00036	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	4.14e-05	0.000359	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	4.14e-05	0.000359	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—FGFR3—urinary bladder cancer	4.12e-05	0.000358	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—RHOA—urinary bladder cancer	4.11e-05	0.000357	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	4.11e-05	0.000356	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	4.11e-05	0.000356	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—GPX1—urinary bladder cancer	4.1e-05	0.000356	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.08e-05	0.000354	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—ERCC2—urinary bladder cancer	4.02e-05	0.000349	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	4.02e-05	0.000349	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—ESR1—urinary bladder cancer	4.01e-05	0.000347	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—S100B—urinary bladder cancer	3.99e-05	0.000346	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.98e-05	0.000345	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—S100B—urinary bladder cancer	3.98e-05	0.000345	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—S100B—urinary bladder cancer	3.94e-05	0.000342	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.92e-05	0.00034	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—RHOA—urinary bladder cancer	3.79e-05	0.000328	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—MTHFR—urinary bladder cancer	3.78e-05	0.000328	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—RHOA—urinary bladder cancer	3.77e-05	0.000327	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.75e-05	0.000325	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—RHOA—urinary bladder cancer	3.74e-05	0.000324	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CREBBP—urinary bladder cancer	3.67e-05	0.000318	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.66e-05	0.000317	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.65e-05	0.000316	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—NQO1—urinary bladder cancer	3.63e-05	0.000315	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IGF1—urinary bladder cancer	3.62e-05	0.000314	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.61e-05	0.000313	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—EGFR—urinary bladder cancer	3.6e-05	0.000312	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NCOR1—urinary bladder cancer	3.59e-05	0.000311	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NCOR1—urinary bladder cancer	3.58e-05	0.00031	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NCOR1—urinary bladder cancer	3.54e-05	0.000307	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.52e-05	0.000306	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CREBBP—urinary bladder cancer	3.51e-05	0.000305	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—IL2—urinary bladder cancer	3.5e-05	0.000303	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—IL2—urinary bladder cancer	3.49e-05	0.000302	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IGF1—urinary bladder cancer	3.47e-05	0.000301	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—IL2—urinary bladder cancer	3.45e-05	0.000299	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—EGFR—urinary bladder cancer	3.45e-05	0.000299	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—KRAS—urinary bladder cancer	3.4e-05	0.000295	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	3.39e-05	0.000294	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	3.34e-05	0.00029	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	3.32e-05	0.000288	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—RHOA—urinary bladder cancer	3.32e-05	0.000288	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CXCL8—urinary bladder cancer	3.31e-05	0.000287	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3.31e-05	0.000287	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CXCL8—urinary bladder cancer	3.28e-05	0.000285	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—KRAS—urinary bladder cancer	3.26e-05	0.000283	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.21e-05	0.000279	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—RHOA—urinary bladder cancer	3.18e-05	0.000275	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—IL2—urinary bladder cancer	3.18e-05	0.000275	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—IL2—urinary bladder cancer	3.17e-05	0.000275	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TERT—urinary bladder cancer	3.16e-05	0.000274	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TERT—urinary bladder cancer	3.15e-05	0.000274	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—IL2—urinary bladder cancer	3.13e-05	0.000272	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TERT—urinary bladder cancer	3.12e-05	0.000271	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.07e-05	0.000266	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—ERBB2—urinary bladder cancer	3.07e-05	0.000266	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PPARG—urinary bladder cancer	3.07e-05	0.000266	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	3.03e-05	0.000263	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CREBBP—urinary bladder cancer	2.95e-05	0.000256	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—ERBB2—urinary bladder cancer	2.94e-05	0.000255	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.93e-05	0.000254	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.92e-05	0.000254	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CXCL8—urinary bladder cancer	2.91e-05	0.000253	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—FGFR3—urinary bladder cancer	2.9e-05	0.000252	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—FGFR3—urinary bladder cancer	2.89e-05	0.000251	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—HRAS—urinary bladder cancer	2.89e-05	0.000251	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—FGFR3—urinary bladder cancer	2.87e-05	0.000249	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ESR1—urinary bladder cancer	2.82e-05	0.000245	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.81e-05	0.000244	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ESR1—urinary bladder cancer	2.81e-05	0.000244	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.8e-05	0.000243	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CXCL8—urinary bladder cancer	2.79e-05	0.000242	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.78e-05	0.000242	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ESR1—urinary bladder cancer	2.78e-05	0.000241	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.78e-05	0.000241	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.78e-05	0.000241	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IL2—urinary bladder cancer	2.78e-05	0.000241	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—HRAS—urinary bladder cancer	2.77e-05	0.00024	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.76e-05	0.000239	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CCND1—urinary bladder cancer	2.71e-05	0.000235	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.71e-05	0.000235	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.71e-05	0.000235	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.67e-05	0.000232	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.66e-05	0.000231	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL2—urinary bladder cancer	2.66e-05	0.000231	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MMP9—urinary bladder cancer	2.63e-05	0.000228	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.63e-05	0.000228	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CDKN1A—urinary bladder cancer	2.62e-05	0.000228	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PTEN—urinary bladder cancer	2.62e-05	0.000227	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.62e-05	0.000227	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCND1—urinary bladder cancer	2.6e-05	0.000225	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.59e-05	0.000225	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.57e-05	0.000223	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.56e-05	0.000222	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.56e-05	0.000222	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.54e-05	0.00022	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.54e-05	0.00022	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MMP9—urinary bladder cancer	2.52e-05	0.000219	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CDKN1A—urinary bladder cancer	2.51e-05	0.000218	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PTEN—urinary bladder cancer	2.51e-05	0.000217	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EP300—urinary bladder cancer	2.5e-05	0.000217	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CREBBP—urinary bladder cancer	2.47e-05	0.000214	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CREBBP—urinary bladder cancer	2.46e-05	0.000214	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	2.46e-05	0.000213	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.45e-05	0.000213	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IGF1—urinary bladder cancer	2.44e-05	0.000212	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CREBBP—urinary bladder cancer	2.44e-05	0.000212	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IGF1—urinary bladder cancer	2.43e-05	0.000211	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.43e-05	0.000211	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—EGFR—urinary bladder cancer	2.43e-05	0.000211	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—SRC—urinary bladder cancer	2.43e-05	0.000211	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—EGFR—urinary bladder cancer	2.42e-05	0.00021	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTGS2—urinary bladder cancer	2.41e-05	0.000209	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IGF1—urinary bladder cancer	2.41e-05	0.000209	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.41e-05	0.000209	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—EGFR—urinary bladder cancer	2.4e-05	0.000208	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EP300—urinary bladder cancer	2.39e-05	0.000207	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.39e-05	0.000207	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—SRC—urinary bladder cancer	2.32e-05	0.000202	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—KRAS—urinary bladder cancer	2.29e-05	0.000199	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—KRAS—urinary bladder cancer	2.29e-05	0.000198	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—KRAS—urinary bladder cancer	2.27e-05	0.000196	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.26e-05	0.000196	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.24e-05	0.000194	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—RHOA—urinary bladder cancer	2.24e-05	0.000194	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—RHOA—urinary bladder cancer	2.23e-05	0.000193	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—RHOA—urinary bladder cancer	2.21e-05	0.000191	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.18e-05	0.000189	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MYC—urinary bladder cancer	2.18e-05	0.000189	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EGFR—urinary bladder cancer	2.13e-05	0.000185	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTEN—urinary bladder cancer	2.1e-05	0.000183	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MYC—urinary bladder cancer	2.08e-05	0.000181	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	2.07e-05	0.00018	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ERBB2—urinary bladder cancer	2.06e-05	0.000179	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ERBB2—urinary bladder cancer	2.04e-05	0.000177	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EGFR—urinary bladder cancer	2.04e-05	0.000177	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—KRAS—urinary bladder cancer	2.01e-05	0.000174	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—EP300—urinary bladder cancer	2.01e-05	0.000174	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.99e-05	0.000173	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	1.96e-05	0.00017	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CXCL8—urinary bladder cancer	1.96e-05	0.00017	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	1.95e-05	0.000169	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—HRAS—urinary bladder cancer	1.94e-05	0.000169	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CXCL8—urinary bladder cancer	1.94e-05	0.000168	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—HRAS—urinary bladder cancer	1.93e-05	0.000167	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—KRAS—urinary bladder cancer	1.93e-05	0.000167	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.92e-05	0.000166	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	1.88e-05	0.000163	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL2—urinary bladder cancer	1.87e-05	0.000162	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL2—urinary bladder cancer	1.85e-05	0.000161	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.83e-05	0.000159	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	1.83e-05	0.000159	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCND1—urinary bladder cancer	1.82e-05	0.000158	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.82e-05	0.000158	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.82e-05	0.000158	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCND1—urinary bladder cancer	1.81e-05	0.000157	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TP53—urinary bladder cancer	1.79e-05	0.000155	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	1.78e-05	0.000154	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MMP9—urinary bladder cancer	1.77e-05	0.000154	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.77e-05	0.000153	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	1.77e-05	0.000153	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CDKN1A—urinary bladder cancer	1.76e-05	0.000153	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.76e-05	0.000153	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PTEN—urinary bladder cancer	1.76e-05	0.000153	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MMP9—urinary bladder cancer	1.75e-05	0.000152	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.75e-05	0.000152	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.75e-05	0.000151	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PTEN—urinary bladder cancer	1.74e-05	0.000151	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TP53—urinary bladder cancer	1.71e-05	0.000148	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—HRAS—urinary bladder cancer	1.71e-05	0.000148	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.69e-05	0.000147	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	1.68e-05	0.000146	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EP300—urinary bladder cancer	1.68e-05	0.000146	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.67e-05	0.000145	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.67e-05	0.000145	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EP300—urinary bladder cancer	1.66e-05	0.000144	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	1.64e-05	0.000142	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—HRAS—urinary bladder cancer	1.64e-05	0.000142	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SRC—urinary bladder cancer	1.63e-05	0.000142	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SRC—urinary bladder cancer	1.62e-05	0.00014	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.6e-05	0.000139	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.57e-05	0.000136	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.57e-05	0.000136	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.48e-05	0.000128	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	1.47e-05	0.000127	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MYC—urinary bladder cancer	1.46e-05	0.000127	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MYC—urinary bladder cancer	1.45e-05	0.000126	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.44e-05	0.000125	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	1.43e-05	0.000124	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.43e-05	0.000124	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EGFR—urinary bladder cancer	1.43e-05	0.000124	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EGFR—urinary bladder cancer	1.42e-05	0.000123	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.37e-05	0.000119	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	1.36e-05	0.000118	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KRAS—urinary bladder cancer	1.35e-05	0.000117	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KRAS—urinary bladder cancer	1.34e-05	0.000116	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.3e-05	0.000113	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.26e-05	0.000109	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.25e-05	0.000108	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	1.2e-05	0.000104	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TP53—urinary bladder cancer	1.2e-05	0.000104	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.2e-05	0.000104	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.2e-05	0.000104	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.19e-05	0.000103	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TP53—urinary bladder cancer	1.19e-05	0.000103	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	1.15e-05	9.99e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.15e-05	9.99e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—HRAS—urinary bladder cancer	1.15e-05	9.96e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HRAS—urinary bladder cancer	1.14e-05	9.87e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	9.43e-06	8.18e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	8.23e-06	7.14e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—EP300—urinary bladder cancer	7.85e-06	6.81e-05	CbGpPWpGaD
